Multidisciplinary Disease Groups are responsible for:

• Vetting each new trial for adequate concepts and protocols or the population they serve and verifying it aligns itself with the SKCC's objectives
  
• Assessing the availability of adequate resources (both financial and feasibility to conduct), participant availability, and existence of pending and open competing trials
  
• Monitoring accrual to open, suspend and close trials in conjunction with the SKCC leadership
  

For questions about MDGs, please contact the CTO Senior Director at Cynthia.Gifford-Hollingsworth@jefferson.edu

The MDG is the first committee that will review an oncology-related study. Note that retrospective chart reviews and correlative lab trials that will utilize banked blood and tissue that do not require informed consent are exempt from MDG review and approval.

The purpose of the MDG is to prioritize and oversee the operations and management of clinical research being conducted within their specific group. There are 7 designated disease groups, and each of them has their own MDG committee. Each committee has a committee leader and a minimum of one co-leader, as well as an MDG coordinator.

There is a specific timeframe in which protocols need to be submitted to the MDG coordinator, and a specific review process. An approval notification is provided.

Institutional Review Board submission preparation should begin after this committee approval is received.